electroCore Completes Sale of New Jersey Tax Benefits

Rhea-AI Summary

electroCore, Inc. (Nasdaq: ECOR) announced the completion of a sale of approximately $211,000 in non-dilutive cash through New Jersey's Technology Business Tax Certificate Transfer program. This program allows qualifying New Jersey-based technology companies to sell net operating loss tax benefits, enabling them to convert tax losses into cash for business growth. Over the past three years, electroCore has received about $2.7 million from this program. CFO Brian Posner emphasized the importance of this funding in supporting their investment in the company's growth and ongoing operations.

Positive

• Received $211,000 in non-dilutive cash from NOL tax benefit sale.
• Cumulatively obtained $2.7 million from New Jersey's tax benefit program over three years.

Negative

• None.

ROCKAWAY, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer program. As a result, the Company has received approximately $211,000 in non-dilutive cash from the sale of these net operating loss (NOL) tax benefits.

“We appreciate the support from the state of New Jersey through its NOL program, which we have benefited from over the past few years,” stated, Brian Posner, Chief Financial Officer of electroCore. “This non-dilutive funding will continue supporting us as we invest in our growing business. We appreciate the support of New Jersey state leadership and the New Jersey Economic Development Authority, which has provided us with approximately $2.7 million of non-dilutive funding over the last three years.”

The New Jersey Technology Business Tax Certificate Transfer program enables qualified, unprofitable NJ-based technology or biotechnology companies with fewer than 225 US employees (including parent company and all subsidiaries) to sell a percentage of their NOL and research and development tax credits to unrelated profitable corporations. NOLs may be sold for at least 80 percent of their value, up to a maximum lifetime benefit of $20 million per business. This allows qualifying technology and biotechnology companies with NOLs to turn tax losses and credits into cash proceeds to fund their growth and operations, including research and development or other allowable expenditures.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving outcomes through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding electroCore's business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally, and other statements that are not historical in nature, particularly those using terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize our products, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.

Contact:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital

FAQ

What is the recent announcement by electroCore about?

electroCore announced it received $211,000 in non-dilutive cash through the New Jersey Technology Business Tax Certificate Transfer program.

How much funding has electroCore received from New Jersey in the last three years?

electroCore has received approximately $2.7 million from New Jersey's tax benefit program over the past three years.

What is the purpose of the New Jersey Technology Business Tax Certificate Transfer program?

The program enables qualifying New Jersey technology companies to sell their net operating loss tax benefits for cash to support their operations and growth.

What is the stock symbol for electroCore?

The stock symbol for electroCore is ECOR.